On the other hand, a different study found that CNS reduction of EphA4 levels with antisense oligonucleotides delivered directly to the central nervous system starting at 49 days of age had no benefit for motor function or survival in two ALS models, including SOD1G93A mice9. The gene discussed is EPHA4; the disease is amyotrophic lateral sclerosis.